HK Stock Market Move | Guangdong Dtech Technology (01377) rose more than 17% in early trading, entering the market on the first day of listing. The company benefits from AI PCB expansion production.
Ding Tai Gao Ke (01377) rose more than 17% in early trading, reaching a high of HK$447.8, a new record high.
Guangdong Dtech Technology (01377) rose more than 17% in early trading, reaching a high of 447.8 Hong Kong dollars, setting a new record. As of the time of writing, it had risen 8.2% to 403.8 Hong Kong dollars, with a trading volume of 4.2 billion Hong Kong dollars.
On the news front, on July 9th, Guangdong Dtech Technology successfully listed on the main board of the Hong Kong Stock Exchange. It was included in the Hong Kong Stock Connect list on the first day of listing. The company is a leading integrated supplier of precision manufacturing solutions, providing tools, materials, and intelligent equipment for key processes in the global PCB manufacturing value chain (including drilling, milling/forming, and other related precision manufacturing processes). According to Frost & Sullivan data, in terms of sales volume, the company is the world's largest drill bit supplier.
CMSC previously pointed out that by 2026, with Meta, Google, and others continuing to strengthen, more PCB factories will join the expansion trend, with a focus on HDI, high-density interconnect, and other high-end AIPCB. The investment scale of some manufacturers is expected to increase several times compared to 2025, driving continued strong demand for drill bits upstream, with a supply-demand mismatch or continuing to exacerbate. Guangdong Dtech Technology is actively promoting overseas production capacity layout, continuously consolidating its competitive advantage, and is expected to fully benefit from this round of AIPCB expansion, with the market share in the high-end drill bit field expected to further increase.
Related Articles

IMMUNEONCO-B(01541): The first patient has been dosed in the Phase II/III clinical trial of IMM0306 for the treatment of IgG4-related diseases.

LEADS BIOLABS-B(09887): Velifexin (PD-L1/4-1BB bispecific antibody Opatezumab monoclonal antibody, LBL-024) has been included in the priority review and approval process for the treatment of advanced pulmonary extrapulmonary neuroendocrine carcinoma.

CEB WATER (01857): "23 China Everbright Water MTN002" will pay interest and redeem on July 17th.
IMMUNEONCO-B(01541): The first patient has been dosed in the Phase II/III clinical trial of IMM0306 for the treatment of IgG4-related diseases.

LEADS BIOLABS-B(09887): Velifexin (PD-L1/4-1BB bispecific antibody Opatezumab monoclonal antibody, LBL-024) has been included in the priority review and approval process for the treatment of advanced pulmonary extrapulmonary neuroendocrine carcinoma.

CEB WATER (01857): "23 China Everbright Water MTN002" will pay interest and redeem on July 17th.

RECOMMEND





